Contact us

Our latest news

Back to news >

Appointment of Paul Gellert

Join us in welcoming Paul Gellert, Seda’s newest consultant, who has recently come on board to expand our complex medicine capabilities. Paul Gellert is a world-renowned expert in his field, with over 33 years’ experience in drug discovery and development, specialising in novel formulation, drug delivery and product design. He has led many projects and teams in identifying, evaluating and designing novel, viable drug delivery-based products and new drug delivery technologies across a broad range of routes of administration and drug modalities. 

From 2017 to 2021, Paul was the AstraZeneca Science & Innovation Director for Drug Delivery and Product Design and he also led AstraZeneca’s Global Novel Drug Delivery Network for many years. Paul is widely recognised as an expert on drug delivery technologies and the external drug delivery environment, including patent and intellectual property aspects. 

Paul has collaborated extensively with academic groups and drug delivery companies and is the co-author and co-inventor of numerous publications and patent applications. He has been a member of a range of external groups including Editorial Advisory Board member for the Nanomedicine journal, Scientific Advisory Board member and Programme Chair for the Controlled Release Society Conference, Scientific Consultant to the Wellcome Trust and EPSRC programme External Advisory Board member. 

Along with the rest of our team of consultants, Paul will provide consultancy support to our clients where necessary, offering his expertise and knowledge surrounding complex medicines. Paul’s expertise will also contribute to our plans to further grow our complex medicine capabilities in the coming months. 

Prof Paul Stott, CEO Seda Pharm Dev Services commented: ‘it is a privilege to be able to work directly with Paul again. I know from first-hand experience the innovation and scientific rigour that Paul brings to everything he does. He will be a tremendous asset to our Clients and an invaluable mentor to our in-house scientists. Welcome Paul!’   

Find out more about our complex medicines capabilities and the expertise we can offer throughout the wider team.